270 Participants Needed

Buloxibutid for Pulmonary Fibrosis

(ASPIRE Trial)

Recruiting at 123 trial locations
TE
CG
TE
BV
Overseen ByBernt Van Den Blink, MD
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Vicore Pharma AB
Must be taking: Licensed IPF therapy
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF.Trial website: www.aspire-ipf.com

Will I have to stop taking my current medications?

If you are on a stable dose of licensed IPF therapy, you can continue taking it during the trial, except for pirfenidone, which is not allowed. If you are not currently on IPF treatment, any previous IPF therapy must have been stopped more than 8 weeks before joining the trial.

How is the drug Buloxibutid different from other treatments for pulmonary fibrosis?

Buloxibutid is unique because it is being studied specifically for its effects on pulmonary fibrosis, whereas existing treatments like pirfenidone have limitations in tolerability and effectiveness. Unlike some other treatments, Buloxibutid may offer a novel approach, potentially improving outcomes for patients with this condition.12345

Who Is on the Research Team?

CG

Cecilia Ganslandt, MD

Principal Investigator

Vicore Pharma AB

Are You a Good Fit for This Trial?

This trial is for people with Idiopathic Pulmonary Fibrosis (IPF), a type of lung scarring. Participants can be on stable IPF therapy or not, but must meet certain health standards to join. Specific inclusion and exclusion criteria details are missing here, so check www.aspire-ipf.com for more info.

Inclusion Criteria

I was diagnosed with IPF within the last 5 years.
I have been on a stable dose of my IPF treatment for at least 8 weeks.
I am not currently on any approved treatment for IPF.
See 7 more

Exclusion Criteria

I have not had a lung infection needing antibiotics in the last 4 weeks.
I have liver problems or a significant liver disease.
I do not have any serious health conditions that could affect the trial.
See 10 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

up to 6 weeks

Treatment

Participants receive either buloxibutid 100 mg BID, buloxibutid 50 mg BID, or placebo BID for 52 weeks

52 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

2-4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Buloxibutid
Trial Overview The ASPIRE trial tests the effectiveness and safety of Buloxibutid taken orally, compared to a placebo. It's designed as a double-blind study where neither participants nor researchers know who gets the real drug versus placebo over 52 weeks.
How Is the Trial Designed?
3Treatment groups
Experimental Treatment
Placebo Group
Group I: Buloxibutid 50 mg BIDExperimental Treatment1 Intervention
For 52 weeks.
Group II: Buloxibutid 100 mg BIDExperimental Treatment1 Intervention
For 52 weeks.
Group III: Placebo BIDPlacebo Group1 Intervention
For 52 weeks.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Vicore Pharma AB

Lead Sponsor

Trials
11
Recruited
1,100+

Population Services International

Collaborator

Trials
25
Recruited
270,000+

Published Research Related to This Trial

In a study of 92 patients with idiopathic pulmonary fibrosis (IPF) receiving pirfenidone, the drug showed an acceptable safety profile, with skin-related (25%) and gastrointestinal (17.5%) adverse events being the most common, leading to discontinuation in 22.5% of cases.
Despite some patients experiencing significant improvements in lung function, the overall decline in lung function (%FVC and %DLCO) was noted over 36 months, highlighting the need for further research through prospective observational registries to better understand pirfenidone's long-term efficacy in real-world settings.
Longitudinal "Real-World" Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece.Tzouvelekis, A., Karampitsakos, T., Ntolios, P., et al.[2022]
In a study involving rats, halofuginone was found to significantly reduce pulmonary fibrosis caused by bleomycin, indicating its potential as a treatment option for this serious condition.
The treatment was administered every second day over a 42-day period, and the results showed a marked decrease in collagen levels in the lungs, highlighting halofuginone's effectiveness in inhibiting collagen type I synthesis associated with fibrosis.
Reduction in pulmonary fibrosis in vivo by halofuginone.Nagler, A., Firman, N., Feferman, R., et al.[2012]
A series of novel derivatives of pirfenidone were designed and synthesized to find new treatments for pulmonary fibrosis, showing promising results in preliminary studies.
Most of these new compounds demonstrated significantly better anti-pulmonary fibrosis activity compared to the original drug, pirfenidone, indicating potential for improved therapeutic options.
Novel pirfenidone derivatives: synthesis and biological evaluation.Yao, M., Sun, M., Chen, C., et al.[2023]

Citations

Longitudinal "Real-World" Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece. [2022]
Reduction in pulmonary fibrosis in vivo by halofuginone. [2012]
Novel pirfenidone derivatives: synthesis and biological evaluation. [2023]
A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects. [2021]
Mouse models of bleomycin-induced pulmonary fibrosis. [2016]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security